SEARCH

SEARCH BY CITATION

References

  • 1
    United Nations Office on Drugs and Crime (UNODC). World Drug Report, UNODC, Vienna, Austria, 2012.
  • 2
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report: The State of the Drugs Problem in Europe, EMCDDA, Lisbon, Portugal, 2011.
  • 3
    Dipartimento Politiche Antidroga (DPA). Relazione annuale al parlamento sull'uso delle sostanze stupefacenti e sulle tossicodipendenze in Italia, DPA, Rome, Italy, 2012.
  • 4
    International Narcotics Control Board (INCB). Report of the International Narcotics Control Board for 2011, United Nations, New York, 2011.
  • 5
    N. Smith. High potency cannabis: the forgotten variable. Addiction 2005, 100, 1558.
  • 6
    D. J. Potter, P. Clark, M. B. Brown. Potency of D9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology. J. Forensic Sci. 2008, 53, 90.
  • 7
    C. J. A. Morgan, H. V. Curran. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192, 306.
  • 8
    R. A. Sewell, M. Ranganathan, D. C. D'Souza. Cannabinoids and psychosis. Int. Rev. Psychiatry 2009, 21, 152.
  • 9
    W. Hall, L. Degenhard. Adverse health effects of non-medical cannabis use. Lancet 2009, 374, 1383.
  • 10
    J. McLaren, W. Swift, P. Dillon, S. Allsop. Cannabis potency and contamination: a review of the literature. Addiction 2008, 103, 1100.
  • 11
    F. Cascini, C. Aiello, G. Di Tanna. Increasing delta-9-tetrahydrocannabinol (D-9-THC) content in herbal cannabis over time: Systematic Review and Meta-Analysis, Curr. Drug Abuse Rev. 2012, 5, 32.
  • 12
    United Nations Office on Drugs and Crime (UNODC). World Drug Report, UNODC, Vienna, Austria, 2006.
  • 13
    S. Ross, M. ElSohly. CBN and 9-THC concentration ratio as an indicator of the age of stored marijuana samples. Bull. Narc. 1997, 49, 139.
  • 14
    I. G. Trofin, C. C. Vlad, G. Dabija, L. Filipescu. Influence of storage conditions on the chemical potency of herbal cannabis. Revista de Chimie 2011, 62, 639.
  • 15
    L. Zamengo, G. Frison, M. Gregio, G. Orrù, R. Sciarrone. Determination of illicit drugs in seized materials: Role of sampling and analysis in estimation of measurement uncertainty. Forensic Sci. Int. 2011, 208, 108.
  • 16
    L. Zamengo, C. Bettin, G. Frison, M. Gregio, R. Sciarrone. Drugs WorkBook (DWB): A tool for the analysis of illicit drugs in seized materials. Sci. Justice, 2013 (in press). Available at http://dx.doi.org/10.1016/j.scijus.2013.03.001 [15 July 2013].
  • 17
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Table PPP-5. Potency of cannabis products at retail level, 2010, http://www.emcdda.europa.eu/stats12/ppptab5a [15 July 2013].
  • 18
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Annual Report 2012: The State of the Drugs Problem in Europe, EMCDDA, Lisbon, Portugal, 2012.
  • 19
    E. L. Sevigny. Is today's marijuana more potent simply because it's fresher?. Drug Test. Analysis 2013, 5, 62.
  • 20
    R. G. Pertwee. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 2006, 147, S163.
  • 21
    J. A. Crippa, G. N. Derenusson, T. B. Ferrari, L. Wichert-Ana, F. L. Duran, R. Martin-Santos et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 2011, 25, 121.
  • 22
    A. W. Zuardi. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008, 30, 271.
  • 23
    A. W. Zuardi, J. A. Crippa, J. E. Hallak, S. Bhattacharyya, Z. Atakan, R. Martin-Santos et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm. Des. 2012, 18, 5131.
  • 24
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). An overview of cannabis potency in Europe, EMCDDA Insights, No. 6, 2004.